Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Finerenone could be another option to SGLT2 inhibitors for this patient population.
Patients with type 2 diabetes can be at risk for developing chronic kidney disease (CKD) or suffering from cardiovascular events, increasing the importance of drugs that can help with all 3 areas of disease.
Recently, researchers presented data showing finerenone reduced the risk of CKD progression, while also lowering the prevalence of cardiovascular events in patients with type 2 diabetes.
In the past, short-term trials produced an association between administration of the nonsteroidal, selective mineralocorticoid receptor antagonist and reduction in albuminuria.
In the latest data, a team led by George Bakris, MD, Department of Medicine, University of Chicago, conducted a double-blind trial examining the effects of the treatment for a median follow-up of 2.6 years.
The data was part of the ongoing Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial, which will assess the drug’s cardiorenal efficacy and safety in populations with type 2 diabetes and less advanced chronic kidney disease.
In an interview with HCPLive®, Bakris explained the results of the study and why finerenone could be added to the list of beneficial treatments for type 2 diabetes patients
Although Bakris said it’s unlikely that finerenone will surpass the use of SGLT2 inhibitors for this patient population, the early results do warrant continued studies.